The clinical-stage gene therapy company Genprex Inc (NASDAQ:GNPX) on Tuesday announced the appointment of Jan Stevens as its vice president of clinical operations.
In her new post, Stevens will take part in supporting clinical development programs for the company’s immunogene therapy Oncoprex, which is currently being evaluated in clinical studies at the MD Anderson Cancer center for the treatment of non-small cell lung cancer.
Stevens will focus in particular on expanding Genprex’s research and clinical development programs, including the expansion of of Genprex’s Oncoprex and Tarceva combination trial across multiple sites in the US.
Stevens, who will join the company’s office in Cambridge, Massachusetts, has served as a clinical consultant to Genprex since June of 2018.
READ: How Genprex took an abandoned pipeline drug and turned it into Oncoprex, an innovative treatment for non-small cell lung cancer
“We are pleased that Jan is joining our growing team in Cambridge, and believe that she will bring her broad experience in managing the clinical operations for our Oncoprex program,” said Julien Pham, president and chief operating officer with Genprex.
Ms Stevens boasts nearly 20 years of clinical operations experience in the biopharma industry and has worked at early to late-stage oncology companies. Before joining Genprex, she held senior roles at Berg LLC and Ziopharm Oncology. She was also previously an acute care nurse in the Neurology unit at Massachusetts General Hospital.
Stevens received her RN degree with clinical affiliations from
Based in Austin, Texas, Genprex, meanwhile, is making great strides toward developing its non-small-cell, lung cancer-fighting, gene-therapy drug Oncoprex. Last March, the company went public, raising $6.4 million. The biopharma is using the funds to continue clinical trials and accelerate development programs into additional drug combinations.
Contact Ellen Kelleher at [email protected]